JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2020-09-28
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well edicotinib (JNJ-40346527) works in treating participants
with acute myeloid leukemia that has come back or does not respond to treatment. JNJ-40346527
may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
Janssen, LP Oregon Health and Science University The Leukemia and Lymphoma Society